Business Context and Reporting Period
Company: Smith & Nephew plc
Filing Type: Form 20-F (Annual Report)
Reporting Period: Fiscal year ended December 31, 2010
Business Overview: A global medical devices company operating in three primary segments: Orthopaedics (reconstruction, trauma, clinical therapies), Endoscopy (arthroscopy/sports medicine), and Advanced Wound Management. The Group operates in over 90 countries with a fiscal year-end of December 31.
Key Financial Metrics (2010)
| Metric | 2010 ($ million) | 2009 ($ million) |
|---|---|---|
| Revenue | 3,962 | 3,772 |
| Operating Profit | 920 | 723 |
| Trading Profit (Non-GAAP) | 969 | 857 |
| Trading Profit Margin | 24.5% | 22.7% |
| Attributable Profit | 615 | 472 |
| Adjusted Attributable Profit (Non-GAAP) | 654 | 580 |
| Basic EPS | 69.3 US cents | 53.4 US cents |
| Adjusted EPS (EPSA) | 73.6 US cents | 65.6 US cents |
| Cash Generated from Operations | 1,111 | 1,030 |
| Trading Cash Flow (Non-GAAP) | 825 | 771 |
| Net Debt | 492 | 943 |
| Capital Expenditure | 315 | 318 |
Material Changes vs. Prior Period
- Revenue Growth: Revenue increased 5% to $3.96 billion. Underlying growth was 4%, with an additional 1% from favorable currency translation. All three segments grew: Orthopaedics (+3%), Endoscopy (+8%), and Advanced Wound Management (+8%).
- Profitability: Operating profit rose 27% to $920 million. Trading profit margin improved by 180 basis points to 24.5%, driven by cost management and efficiency programs.
- Debt Reduction: Net debt decreased significantly by $451 million (48%) to $492 million, primarily due to a reduction in long-term borrowings and strong operating cash flow.
- Segment Performance: Advanced Wound Management saw a 46% increase in trading profit, aided by a $25 million legal settlement regarding NPWT intellectual property and cost savings from a new China facility.
Guidance, Outlook, and Risks
Outlook and Management Commentary
- 2011 Expectations: Management expects Orthopaedic Reconstruction to grow above the market rate, driven by knee franchise momentum. Endoscopy is expected to achieve above-market growth in arthroscopy repair. Advanced Wound Management is projected to continue growing above the market rate.
- Margin Strategy: The Group anticipates that the cost of new investments (geographic expansion and new products) will broadly offset further efficiency savings in the short to medium term.
- Leadership Transition: David Illingworth is retiring as CEO; Olivier Bohuon is appointed to succeed him effective April 14, 2011.
Risks and Contingencies
- Legal Proceedings:
- Macrotexture Claims: Related to OXINIUM femoral knee components. Aggregate cost to date is ~$212 million. A $20 million provision remains; the Group is litigating with excess insurance carriers for the remaining ~$133 million.
- FCPA Investigation: Ongoing informal investigation by the SEC and DOJ regarding potential Foreign Corrupt Practices Act violations by distributors. Discussions for a settlement are underway.
- Patent Litigation: Ongoing disputes with Kinetic Concepts (KCI) regarding NPWT patents and Arthrex regarding suture anchors.
- Market Risks: Exposure to currency fluctuations (USD, Sterling, Euro), government reimbursement policies, and pricing pressures in healthcare markets.
Key Facts for Investor Verification
- Non-GAAP Reconciliations: Verify the reconciliation of "Trading Profit" and "Adjusted EPS" to GAAP figures, as these exclude significant restructuring, acquisition, and impairment costs.
- Insurance Recovery: Monitor the status of the $133 million claim against excess insurance carriers regarding the macrotexture knee component litigation.
- FCPA Settlement: Track the outcome of the ongoing discussions with the SEC and DOJ regarding the Foreign Corrupt Practices Act investigation.
- CEO Transition: Assess the integration and strategic direction under the new CEO, Olivier Bohuon, following the April 2011 transition.
- Debt Covenants: Confirm continued compliance with banking facility covenants (Net Debt/EBITDA ratio not to exceed 3.0:1).